STOCK TITAN

Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) will report second quarter financial results on August 10, 2023. A conference call will be held at 9:00 AM ET to review financial results and provide corporate updates.
Positive
  • Alimera Sciences will report second quarter financial results on August 10, 2023, which could positively impact stock price if the results exceed expectations.
Negative
  • None.

Conference Call to be held the same day at 9:00am Eastern Time

ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report second quarter financial results on August 10, 2023, prior to the market open.

Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management’s formal remarks there will be a question-and-answer session.

Participants are asked to pre-register for the call.

Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without Internet access or who are unable to pre-register may dial in by calling 1-844-839-2190 (domestic) or 1-412-717-9583 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

The conference call will also be available through a live webcast, which is also available through the company’s website.

A webcast replay of the call will be available approximately one hour after the end of the call through August 24, 2023. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 4988159. The telephonic replay will be available until November 10, 2023.

About Alimera Sciences, Inc.
Alimera Sciences a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

For press inquiries:For investor inquiries:
Jules AbrahamScott Gordon
for Alimera Sciencesfor Alimera Sciences
917-885-7378scottg@coreir.com
julesa@coreir.com 


FAQ

When will Alimera Sciences report its second quarter financial results?

Alimera Sciences will report its second quarter financial results on August 10, 2023.

What time is the conference call?

The conference call will be held at 9:00 AM ET.

How can I participate in the conference call?

Participants can pre-register for the call to receive their dial-in number, or dial in directly using the provided numbers.

Will there be a webcast of the conference call?

Yes, the conference call will be available through a live webcast on the company's website.

How long will the webcast replay be available?

The webcast replay will be available for approximately one hour after the end of the call through August 24, 2023.

Alimera Sciences, Inc.

NASDAQ:ALIM

ALIM Rankings

ALIM Latest News

ALIM Stock Data

154.55M
8.06M
8.75%
91.96%
0.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ALPHARETTA

About ALIM

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.